Abstract
Background and aims Large interindividual variability in achieved low-density lipoprotein cholesterol (LDL-C) concentration is known for statin recipients. Systematic profiling of cellular lipid trafficking pathways was performed to elucidate how biological variation contributes to treatment outcomes of statin therapy.
Methods Using a multiplexed imaging platform 26 readouts for cellular lipid trafficking were obtained from leukocyte subpopulations for each person, including LDL uptake (UPT), lipid storage (LiM) and three combined lipid trafficking scores (LT-P, LT-R, LT). With this pipeline 400 subjects of the FINRISK 2012 Study were analysed, including 200 recipients of cholesterol-lowering medication.
Results Large interindividual variability of cellular LDL uptake and lipid storage was observed. Both LDL uptake and LT score associated negatively with LDL-C for statin recipients and the associations strengthened with increase in statin intensity, explaining up to 25% of LDL-C variability. Integration of LT score with a polygenic risk score for LDL-C further increased the association strength. High-intensity statin (HIS) recipients in the lowest quintile of LT score displayed a pro-atherogenic lipoprotein profile containing more VLDL, IDL and LDL particles with altered lipid content as compared to subjects in the highest quintile of the score. Subjects in the lowest quintile of the LT-R score had lower odds to be at their target LDL-C level and subjects in the lowest quintile of LiM score had higher odds to experience a cardiovascular event as compared to the rest of the HIS recipients.
Conclusions Interindividual variation in cellular lipid trafficking pathways can contribute to the variability of statin therapy outcomes and provide new opportunities for treatment optimization and risk assessment in cardiovascular disease.
Translational perspective Most high-risk patients do not achieve their LDL-C target levels and have limited access to lipid-lowering treatment (LLT) beyond statins. Here we highlight that cellular readouts for lipid uptake and storage can be used to understand why statin therapy benefits some patients more than others. This can open new avenues for precision medicine applications for easier selection of optimal LLT and improved cardiovascular risk assessment.
Competing Interest Statement
A patent application covering the use of the here-suggested patient stratification methods has been filed (application: WO2022123120A1), in which University of Helsinki is the applicant and S.G.P. is an inventor.
Funding Statement
Grants from the Academy of Finland 328861 and 325040, Business Finland (Research to Business) 1821/31/2021, Magnus Ehrnrooth and the Foundation for Cardiovascular Research to S.G.P. Grants from Academy of Finland Center of Excellence in Complex Disease Genetics 312062, Academy of Finland 285380, the Finnish Foundation for Cardiovascular Research and the Sigrid Jusélius Foundation to S.R. Funding from the Doctoral Programme in Population Health, University of Helsinki to M.T.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Peripheral blood mononuclear cell (PBMC) samples were cryopreserved in 2012 as a part of Finnish population survey, FINRISK 2012, with written consent and ethical approval of the Hospital District of Helsinki and Uusimaa (permit 162/13/03/00/2011). The FINRISK 2012 sample collection was then transferred to THL Biobank in 2015. Frozen PBMC samples, pseudonymised donor-linked lipid values and survey data were obtained then from THL Biobank (www.thl.fi/biobank) and used under Biobank agreement (THLBB2020_7). The rigister-based pseudynymised data was obtained under permit (THL/4640/14.02.00/2020) from the Finnish Social and Health Data Permit Authority Findata.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this article were provided by THL Biobank (www.thl.fi/biobank) and used under Biobank agreement THLBB2020_7. Access to the data can be obtained from the THL Biobank through the standard application procedure. The register-based data used in this study can be obtained from the Finnish Social and Health Data Permit Authority Findata by submitting a data permit application. Description of the register data (names of registers and attribute codes) can be obtained from the corresponding author.
